Project FrontRunner is a paradigm shift in regulatory guidance that is moving oncology drug development into earlier stages of disease. The expectations from oncology drug developers will be to adapt their trial design, using fewer single-arm studies and instead shifting focus to randomized control trials that focus on development earlier in the cancer treatment pathway. IQVIA is here to help you navigate the changing landscape and partner with you to bring novel therapies to cancer patients faster.
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.
Access new resources for advanced therapy development, from candidate identification through market authorization.
Unravel the complexities of cancer treatment with patient-level data-driven solutions.
.svg){kind=icon}
